Jaguar Health Inc. (JAGX) saw its shares decline by 10% on Tuesday following the release of its second-quarter earnings, which missed analyst expectations. The company reported a wider-than-expected loss and lower-than-anticipated revenue, although it did see growth in its Mytesi prescription volume. Despite the setbacks, Jaguar remains optimistic about the future, with plans to launch its FDA-approved Gelclair product in October and ongoing development of treatments for rare diseases.